Acquired by Biogen in Oct 2023
RETA - Reata Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Plano,
United States
Type: Equity
RETA price evolution
RETA
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $48.84 | $84.94 | $42.31 | $31.92 |
| Short term investments | $281.37 | $236.02 | $345.2 | $403.96 |
| Net receivables | $22.66 | |||
| Inventory | $13.28 | $5.71 | ||
| Total current assets | $401.85 | $332.54 | $397.77 | $445.1 |
| Long term investments | ||||
| Property, plant & equipment | $89.9 | $114.87 | $116.44 | $138.4 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $100.74 | $121.04 | $116.72 | $138.54 |
| Total investments | $281.37 | $236.02 | $345.2 | $403.96 |
| Total assets | $502.59 | $453.58 | $514.49 | $583.64 |
| Current liabilities | ||||
| Accounts payable | $19.86 | $14.45 | $18.71 | $7.52 |
| Deferred revenue | ||||
| Short long term debt | $2.46 | $3.21 | $2.15 | $5.25 |
| Total current liabilities | $125.09 | $54.6 | $58.96 | $50.71 |
| Long term debt | $163.55 | $114.73 | $117.31 | $135.46 |
| Total noncurrent liabilities | $290.2 | $529.66 | $521.23 | $528.42 |
| Total debt | $166 | $117.93 | $119.46 | $140.71 |
| Total liabilities | $415.3 | $584.25 | $580.19 | $579.13 |
| Shareholders' equity | ||||
| Retained earnings | -$1490.65 | -$1683.65 | -$1567.53 | -$1482.03 |
| Other shareholder equity | ||||
| Total shareholder equity | $87.29 | -$130.67 | -$65.69 | $4.52 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $42.31 | $590.26 | $818.15 | $664.32 |
| Short term investments | $345.2 | |||
| Net receivables | $22.23 | |||
| Inventory | ||||
| Total current assets | $397.77 | $596.48 | $847.34 | $669.28 |
| Long term investments | ||||
| Property, plant & equipment | $116.44 | $138.38 | $4.91 | $3 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $116.72 | $138.54 | $10.26 | $13.14 |
| Total investments | $345.2 | |||
| Total assets | $514.49 | $735.02 | $857.6 | $682.42 |
| Current liabilities | ||||
| Accounts payable | $18.71 | $13.51 | $4.79 | $1.91 |
| Deferred revenue | $1.65 | $4.69 | $9.39 | |
| Short long term debt | $2.15 | $3.14 | ||
| Total current liabilities | $58.96 | $53.99 | $119.2 | $192.01 |
| Long term debt | $117.31 | $132.89 | $155.02 | |
| Total noncurrent liabilities | $521.23 | $495.03 | $320.96 | $233.55 |
| Total debt | $119.46 | $136.03 | $155.02 | |
| Total liabilities | $580.19 | $549.03 | $440.17 | $425.56 |
| Shareholders' equity | ||||
| Retained earnings | -$1567.53 | -$1255.63 | -$958.25 | -$710.49 |
| Other shareholder equity | ||||
| Total shareholder equity | -$65.69 | $185.99 | $417.43 | $256.86 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $22.75 | $0.2 | $0.54 | |
| Cost of revenue | $0.85 | |||
| Gross Profit | $21.9 | $0.2 | $0.54 | |
| Operating activities | ||||
| Research & development | $57.12 | $55.48 | $47.22 | $43.48 |
| Selling, general & administrative | $45.69 | $54.88 | $32.02 | $27.27 |
| Total operating expenses | $114.1 | $110.65 | $79.52 | $71.03 |
| Operating income | -$92.2 | -$110.45 | -$79.52 | -$70.49 |
| Income from continuing operations | ||||
| EBIT | -$92.2 | -$110.45 | -$79.52 | -$70.49 |
| Income tax expense | -$0.06 | |||
| Interest expense | -$285.2 | $5.66 | $6.03 | $8.52 |
| Net income | ||||
| Net income | $193 | -$116.12 | -$85.5 | -$79 |
| Income (for common shares) | $193 | -$116.12 | -$85.5 | -$79 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.22 | $11.49 | $9.02 | $26.52 |
| Cost of revenue | ||||
| Gross Profit | $2.22 | $11.49 | $9.02 | $26.52 |
| Operating activities | ||||
| Research & development | $169.84 | $155.99 | $159.08 | $128.11 |
| Selling, general & administrative | $109.28 | $99 | $75.13 | $58.3 |
| Total operating expenses | $280.25 | $256.2 | $235.34 | $311.74 |
| Operating income | -$278.03 | -$244.71 | -$226.32 | -$285.22 |
| Income from continuing operations | ||||
| EBIT | -$278.03 | -$244.71 | -$226.32 | -$285.22 |
| Income tax expense | -$0.03 | -$0.45 | -$22.49 | $0.01 |
| Interest expense | $33.89 | $53.13 | $43.91 | $4.94 |
| Net income | ||||
| Net income | -$311.9 | -$297.39 | -$247.75 | -$290.17 |
| Income (for common shares) | -$311.9 | -$297.39 | -$247.75 | -$290.17 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | $193 | -$116.12 | -$85.5 | -$79 |
| Operating activities | ||||
| Depreciation | $0.29 | $0.29 | $0.28 | $0.27 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $20.36 | $38.06 | $14.98 | $14.45 |
| Total cash flows from operations | -$69.93 | -$81.45 | -$50.43 | -$46.53 |
| Investing activities | ||||
| Capital expenditures | -$0.27 | -$0.14 | -$0.37 | -$0.34 |
| Investments | -$42.67 | $111.14 | $60.87 | -$68.8 |
| Total cash flows from investing | -$42.95 | $111 | $60.51 | -$69.14 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.8 | $0 | ||
| Net borrowings | $72.17 | |||
| Total cash flows from financing | $76.78 | $13.08 | $0.31 | $0.44 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$36.1 | $42.63 | $10.39 | -$115.24 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$311.9 | -$297.39 | -$247.75 | -$290.17 |
| Operating activities | ||||
| Depreciation | $1.13 | $1.2 | $1.14 | $0.93 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $58.73 | $56.81 | $57.63 | $26.38 |
| Total cash flows from operations | -$204.27 | -$235.7 | -$322.34 | -$251.15 |
| Investing activities | ||||
| Capital expenditures | -$3.27 | -$1.33 | -$0.93 | -$2.67 |
| Investments | -$341.89 | |||
| Total cash flows from investing | -$345.16 | -$1.33 | -$0.93 | -$2.67 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $333.28 | $492.56 | ||
| Net borrowings | -$167.17 | $75 | ||
| Total cash flows from financing | $1.49 | $9.14 | $477.09 | $580.36 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$547.95 | -$227.89 | $153.83 | $326.53 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 37.85M |
| Revenue | $23.48M |
|---|---|
| EBITDA | -$351.54M |
| EBIT | -$352.67M |
| Net Income | -$87.62M |
| Revenue Q/Q | 2.89K% |
| Revenue Y/Y | 134.81% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 2.31 |
| Cash/Share | 1.29 |
| EPS | -$2.32 |
|---|---|
| ROA | -17.06% |
| ROE | 335.20% |
| Debt/Equity | -8.83 |
|---|---|
| Net debt/EBITDA | -1.04 |
| Current ratio | 3.21 |
| Quick ratio | 3.11 |